Details
Stereochemistry | RACEMIC |
Molecular Formula | C6H14N2.4Cl.Pt |
Molecular Weight | 451.085 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | -4 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[Cl-].[Pt].N[C@@H]1CCCC[C@H]1N
InChI
InChIKey=QQDHPPCYXJYODE-RQDPQJJXSA-J
InChI=1S/C6H14N2.4ClH.Pt/c7-5-3-1-2-4-6(5)8;;;;;/h5-6H,1-4,7-8H2;4*1H;/p-4/t5-,6-;;;;;/m1...../s1
Molecular Formula | C6H14N2 |
Molecular Weight | 114.1888 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Pt |
Molecular Weight | 195.084 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26865551Curator's Comment: Description was created based on several sources, including
http://www.medkoo.com/products/5702
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26865551
Curator's Comment: Description was created based on several sources, including
http://www.medkoo.com/products/5702
Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. Ormaplatin showed marked
antitumor activity both in vitro and vivo. The severe, cumulative and irreversible peripheral neurotoxicity observed in phase I studies resulted in termination of further clinical development of ormaplatin.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.78 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
98 mg/m² single, intravenous dose: 98 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.576 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
78 mg/m² single, intravenous dose: 78 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.995 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
123 mg/m² single, intravenous dose: 123 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.37 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
98 mg/m² single, intravenous dose: 98 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.62 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
78 mg/m² single, intravenous dose: 78 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.05 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
123 mg/m² single, intravenous dose: 123 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.9 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
98 mg/m² single, intravenous dose: 98 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
78 mg/m² single, intravenous dose: 78 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.5 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
123 mg/m² single, intravenous dose: 123 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
98 mg/m² single, intravenous dose: 98 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
78 mg/m² single, intravenous dose: 78 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8306332 |
123 mg/m² single, intravenous dose: 123 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PLATINUM (IV) ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10555124
A phase I trial of ormaplatin administered as a 1-h infusion every 4 weeks was performed. Forty-one patients received 101 cycles of drug over the dose range 4-128 mg/m2.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8185678
10 uM tetraplatin (ormaplatin) is cytotoxic for L1210 leukemia cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:38:28 GMT 2023
by
admin
on
Sat Dec 16 17:38:28 GMT 2023
|
Record UNII |
SFK1SGY8V1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1450
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
85577
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
BB-61
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
363812
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
SFK1SGY8V1
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
276017
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
SUB09461MIG
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
155491093
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
DTXSID50897225
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
100000083327
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
C1250
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
6603
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY | |||
|
62816-98-2
Created by
admin on Sat Dec 16 17:38:28 GMT 2023 , Edited by admin on Sat Dec 16 17:38:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |